NCT03470077View on ClinicalTrials.gov

Effect of Intravenous Nalbuphine on Emergence Agitation

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

July 31, 2019

Primary Completion Date

September 30, 2020

Study Completion Date

December 1, 2020

Conditions
Postoperative Complications
Interventions
DRUG

IV nalbuphine 0.1 mg/kg with induction of anesthesia.

"Group A: 40 patients will receive IV nalbuphine 0.1 mg/kg with induction of anesthesia.~."

DRUG

IV nalbuphine 0.1 mg/kg at the end of surgery.

Group B: 40 patients will receive IV nalbuphine 0.1 mg/kg at the end of surgery just before discontinuation of anesthesia.

Trial Locations (1)

71515

Assiut University Hospital, Asyut

All Listed Sponsors
lead

Assiut University

OTHER

NCT03470077 - Effect of Intravenous Nalbuphine on Emergence Agitation | Biotech Hunter | Biotech Hunter